WHO Brief Biography- on the public health response for the prevention of mother to child transmission of hepatitis B virus infection – 2019 Manal Hamdy El-Sayed ,

Dr. Manal El-Sayed (Cairo, Egypt) is Professor of Pediatrics at . She is the clinical director of the national HCV Pediatric treatment program and the director of the clinical research unit and co-supervisor of the viral hepatitis treatment center at Ain Shams University. Manal has worked with pediatric hematology and oncology teams at Ain Shams University, National Cancer Institute, and 57357 Children’s Cancer Hospital since 1990. Manal is a founding member of the Egyptian National Committee for Control of Viral Hepatitis (NCCVH) charged with planning and implementing the nationwide program for prevention and management of viral hepatitis since 2006. She contributed to the establishment of a nationwide network of 55 specialized liver centers that provided interferon therapy to 350,000 HCV-infected patients. Since 2014 when the NCCVH introduced the new direct-acting antiviral agents for HCV, more than 3 million patients have been treated. Manal collaborated on the development of the national action plan for prevention and control of viral hepatitis published in October 2014 with representatives from WHO, the U.S. Centers for Disease Control and Prevention (U.S. CDC), Pasteur Institute, and national stakeholders. In addition to co-supervising the nationwide mass screening program for adults and children reaching so far more than 56 million people. Manal is also an active board member and secretary general of the Egyptian Liver Care Society, a non-governmental organization that offers financial assistance to patients receiving treatment for hepatitis or liver transplants. She has authored and co-authored numerous journal articles on hepatitis and liver diseases, and participated in the development of WHO’s HBV, HCV and diagnostic guidelines. From 2011-2015, Manal was Vice Chair of WHO’s Technical Advisory Group for Prevention and Control of Viral Hepatitis in Egypt. She is also a board member of the European Study of Liver Disease International Liver Foundation since January 2018. In addition to be an oversight committee member of the EndHep2030 initiative since the beginning of 2019.

Wang Ailing National Center for Women and Children’s Health Chinise Center Beijing, China

1996-2002, Resident Doctor, Beijing maternal and children’s health (MCH) hospital. 2003 to now, Department of women’s health, and Department of Maternal Health, National Center for Women and Children’s Health (NCWCH), China CDC. As a team leader, in charge of technical support for national PMTCT program and give technical support for maternal health on the national level. Participated all six versions of PMTCT guidelines in China.

Alice Nanelin Guingane Centre Hospitalier Universitaire Yalgado Ouédraogo ,

Guingane N Alice is a hepato-gastroenterologist at the University Hospital Center Yalgado Ouedraogo in Ouagadougou, Burkina Faso. She completed her medical degree in 2009 at University of Ouagadougou and Master of public health in 2015 at Aix Marseille University, . She is currently a PhD student at Montpelier University, France. She also graduated in clinical research from the Pasteur Institute of Paris. Her research activities are mainly focused on the prevention and management of viral hepatitis in pregnant women. She is assistant research officer of the Burkinabe Society of Hepato- gastroenterology. She is also a permanent member of the plenary session of the AC45 "clinical research on viral hepatitis" and the sub-working group "screening-prevention" coordinated by Pr Karine Lacombe and Dr. Hélène Fontaine.Since 2016 she works with the National Agency for Research on AIDS and Viral Hepatitis (ANRS) on the project ANRS 12359 which aims at the prevention of mother-to-child transmission of the hepatitis B virus.Daily, she manages a cohort of more than 1500 pregnant women infected with the hepatitis B virus at the University Hospital Center Yalgado Ouedraogo in Ouagadougou, Burkina Faso.

Benjamin Cowie University of Melbourne Melbourne, Australia

Professor Benjamin Cowie is an Infectious Diseases Physician and epidemiologist, with appointments at the Victorian Infectious Diseases Reference Laboratory, Doherty Institute and the Royal Melbourne Hospital. In addition, Ben is a medical epidemiologist with Communicable Disease Epidemiology and Surveillance, Victorian Department of Health and Human Services, and is a Professorial Fellow in the Department of Medicine at the University of Melbourne. He serves on a range of communicable disease, clinical and public health committees at state, national and international levels – including the Hepatitis B Expert Resource Panel and the Strategic and Technical Advisory Committee for Viral Hepatitis for the WHO Western Pacific Region, and the Strategic Information and Modelling Reference Group for the WHO Global Hepatitis Programme. Ben has built a broad research agenda in the epidemiology and control of communicable diseases, and has established a research group whose focus is epidemiological and public health research in viral hepatitis. Ben has been involved in the development of health public policy in relation to viral hepatitis in Australia and internationally, and in 2015 was named the inaugural Director of the WHO Collaborating Centre for Viral Hepatitis (www.doherty.edu.au/whoccvh) at the Doherty Institute.

Chipepo Kankasa University Teaching Hospital Lusaka,

Chipepo Kankasa has worked as Medical Doctor for the past 30 years, and as a Consultant Paediatrician for the past 20-years; worked as a researcher of viral perinatal studies from 1997 to date (HIV & HHV-8). With support from Horizon Pop Council, served as PI of a study that tested the "Feasibility of using ARVs in a Country of Poor Resource Setting" (1998 to 2001) to prevent mother to child HIV transmission (PMTCT), found it was feasible and the national program started using maternal AZT for PMTCT from 2002. Chaired the first technical working group (TWG) that developed the first national guidelines on PMTCT in 2002; served as national Chairperson of the PMTCT Technical Working Group for almost 20 years; currently serve as Chairperson of the National ART-TWG. National Technical working groups are responsible for developing and/or domesticating and formulation of National Guidelines. As we strive to eliminate perinatal HIV, the hepatitis "B" virus (HBV) epidemic is gaining ground, using lessons learned from the HIV-PMTCT programme, we should now strive to eliminate HBV-MTCT by timely treating pregnant women infected with HBV with ARVs in a addition to timely birth vaccination of babies to prevent HBV acquisition.

Cihan Yurdaydin Koc University Istanbul, Turkey

Cihan Yurdaydin specialized in Internal Medicine at the University of Ankara Medical School, Turkey, after gaining his medical degree from the same establishment. After a year of national service at Gümüssuyu Military Hospital and two years at Van State Hospital, he returned to the University of Ankara Medical School to specialize in gastroenterology. Dr. Yurdaydin has worked for one year on hepatic encephalopathy at the University of Vienna, Austria and was a visiting fellow at the Liver Diseases Section of the National Institutes of Health in Bethesda, MD, between 1991 and 1993.Professor Yurdaydin left Ankara University on January 31, 2019 and is currently working in the Department of Gastroenterology and Hepatology at Koc University Medical School in Istanbul. Professor Yurdaydin was an Editorial Board member of the Journal of Hepatology from 1995 to 2000 and has been Editor-in-Chief of The Turkish Journal of Gastroenterology from 1999 until December 2013. Prof.Yurdaydin has published and has served as a reviewer in peer reviewed journals such as Gastroenterology, Hepatology, Journal of Hepatology, Lancet and The New England Journal of Medicine. He has published more than 140 articles and his papers have received more than 6500 citations. He has served in the Scientific Committee of EASL between 2000 and 2003 and as Councillor from 2013 to 2015. He has also served the World Gastroenterology Organization at various positions and is currently the President of this organization.

Deborah Odoh Federal Ministry of Health, , Nigeria

Deborah Odoh is a Public Health Physician who has worked with the Federal Ministry of Health, Nigeria since 2001. She was involved in the development of the National Strategic Plan for the Control of Viral Hepatitis in Nigeria and the National Guideline for the Prevention, Control and Treatment of Viral Hepatitis in Nigeria which were published in 2016. A significant part of her career was spent in the HIV programme where she worked for 6 (six) years as the national desk officer for the MOH's prevention of mother to child transmission of HIV programme. Since 2004 she has been involved in the process of adaptation of WHO HIV and Hepatitis guidelines to national documents. She is currently a Deputy Director at the MOH, heading the Prevention Branch and oversees the following Units - HIV Testing, PMTCT, Hepatitis and Sexually Transmitted Infections (STIs).

Elizabeth Mason London School of Hygiene and Tropical Medicine London, United Kingdom

Former Director of the Department of Maternal, Newborn, Child and Adolescent Health (MNCAH) at the World Health Organisation (WHO) with more than 40 years’ experience in evidence based policy and strategy development; project and programme planning, management, implementation and monitoring & evaluation of maternal, newborn, child and adolescent health programmes at all levels of the health system; Key areas of interest are improving quality of care and making health systems work for mothers and children. She was instrumental in the initiation and implementation of EPI in in the 1980’s, has been a member of various immunization advisory committees including MNTE, Maternal Immunization and Antenatal Care project, and WPR HepB/PMTCT. She qualified in Medicine from the University of Leeds, has an MSc from the London School of Hygiene and Tropical Medicine, is a Fellow of the Faculty of Public Health, UK, an Honorary Professor at the London School of Hygiene and Tropical Medicine and an Honorary Fellow of the Institute for Global Health, UCL, UK.

Fernanda Fernandes Fonseca Ministry of Health Brasilia, Brazil

Fernanda Fernandes Fonseca currently is a technical advisor at the Department of STIs, HIV/AIDS and Viral Hepatitis, Ministry of Health of Brazil, responsible for the Brazilian response to the prevention of mother to child transmission of HIV, syphilis and viral hepatitis. Active participant of the update of Brazilian protocols and guidelines on HIV, STI and viral hepatitis, is accustomed to use the latest scientific evidence, as well as WHO protocols and manuals to support public health decision-making and planning and to improve the care and surveillance of STI, HIV and viral hepatitis.

Fernando de la Hoz National university of Colombia Bogota, Colombia

I have been working on hepatitis B epidemiology in Colombia since 1989. I have participated in the construction of the epidemiological situation for the last 5 years working together with PAHO and the Colombian Ministry of Health. I have participated in field studies aimed to evaluate the current level of transmission of hepatitis B and the field effectiveness of hepatitis B vaccination in Colombia in high endemic populations. Also, I have participated in studies assessing the impact of vaccination on the occurrence of chronic liver diseases in my country. In addition, I participated in the update to the WHO position paper on hepatitis B vaccination. As such, I participated in several literature reviews aimed to clarify several aspects of hepatitis B vaccination such as use of birth dose in developing countries, barriers for birth dose introduction and coverage, use of hepatitis B vaccine among immunocompromised individuals, among others.

Adeniyi Oluwafunmilayo Funke University of Lagos, Nigeria

Dr. Adeniyi is a Senior lecturer in the department of Paediatrics College of Medicine and Honorary Consultant at the Lagos University Teaching Hospital Idi Araba, Lagos. She is a Paediatric gastroenterologist with focus on paediatric gastrointestinal infection, motility disorders and liver disease in children. Dr Adeniyi has an undergraduate degree in Medicine and Surgery(MBBS) and graduated from University of in March 1994. She also has a fellowship of the National Postgraduate Medical College (Faculty of Paediatrics) in May 2002. She holds a master’s in child Heath from the University of Warwick, United Kingdom obtained in December 2006 and a Certificate of Training in Paediatric Gastroenterology from Stellenbosch University, CapeTown obtained in March 2017. Over the past 12 years, I have been actively involved in teaching, clinical service and research especially in the area of general pediatrics and pediatrics gastroenterology, hepatology and nutrition. My research interests have been on gastrointestinal bleeding, peptic ulcer and helicobacter pylori infection, food allergy, hepatitis, inflammatory bowel disease in children and GI endoscopic procedure findings. My research has been multi-faceted and covers aspects of health-care from the laboratory bench to the community. I have also been involved in inter departmental collaboration and international partnerships in order to achieve research which has both local relevance and contributes significantly to knowledge and practice even at the international level. I recognize the value of team approach and work constantly with both senior and junior professional colleagues. I have mentored several undergraduate students and supervised the dissertation and thesis of 7 postgraduate students (Fellowship and master’s degree) whom I have also mentored. These dissertations include research on the prevalence of hepatitis in apparently healthy Nigerian children and coinfection of Hepatitis B and C in children with Human Immunodeficiency virus infection. Presently, I have attained the membership of several professional and academic bodies namely the National Postgraduate Medical College of Nigeria (Faculty of Paediatrics), Paediatric association of Nigeria, Society of Gastroenterology and Hepatology in Nigeria, the Nigerian Society of Paediatric Gastroenterology,Hepatology and Nutrition, European Society of Paediatric Gastroenterology, Hepatology and Nutrition to mention a few. I have over 26 publications on research carried out in both general paediatrics and in the field of paediatric gastroenterology, hepatology and nutrition. I have been opportuned to have had a scholarship award granted by the Ford Foundation organization for a master’s degree in Child Health at the University of Warwick in the united kingdom (2005-2006); Clinical training award in Paediatric Gastroenterology, hepatology and Nutrition at Red Cross Hospital , South by Nestle Nutrition Institute. I have also had additional clinical training at the Tygerberg hospital / Stellebosch University in Cape Town, . Presently, I have also obtained a Central research grant from the University of Lagos to carry out a research on malnourished children in Lagos.

Gonzague Jourdain Chiang Mai University Chiang Mai, Thailand

Clinical epidemiologist trained in medicine and statistics in France with a long experience in designing, implementing and analyzing clinical research studies in Europe and in South East Asia, with a special interest in prevention interventions that can be implemented in resource limited settings. Was co-investigator and principal investigator of several clinical trials assessing simplified methods to prevent perinatal transmission of HIV until 2012. Was the principal investigator of a randomized, double-blind, clinical trial (iTAP, NCT01745822, 2013-2018), which assessed the efficacy and safety of a short maternal course of tenofovir disoproxil fumarate to prevent perinatal transmission of hepatitis B (HB) virus in HBeAg-positive women and infants receiving HB vaccine and HB immune globulin. Currently conducting a second trial (iTAP-2, NCT03343431) to assess the possibility to omit the administration of immune globulin to the newborn when the mother takes tenofovir disoproxil fumarate during the last trimester of pregnancy and 2 months postpartum.

Hiromi Obara National Center for Global Health and Medicine Japan Tokyo, Japan

Dr Hiromi OBARA, MD, MSc, Specialist of Ob/Gyn, has over 20 years’ experience providing technical, programmatic and management support in reproductive, maternal and newborn health (RMNH) to several countries in the Western Pacific Region and elsewhere. Positions held include JICA Health Policy Advisor in Lao PDR, Reproductive Health Medical Officer in WHO Western Pacific Regional Office, Deputy Director of the International Affairs Division of Ministry of Health, Labour and Welfare, Japan, Chief Advisor of JICA MCH project in Cambodia, Ob/Gyn doctor in Jichi Medical University Hospital in Japan. She obtained an MSc in Epidemiology at the London School of Hygiene and Tropical Medicine. She assisted countries in the Western Pacific Region to conduct maternal death reviews, improve newborn care, eliminate unsafe abortions, develop policy strategy frameworks and conduct monitoring both at country and regional levels. She has also contributed to regional and global meetings as an RMNH expert, to WHO publications, as a member of the Guideline Development Group and the Independent Review Group. Her professional interests include programme implementation, monitoring and evaluation, quality of care, updating country policies/strategies/plans/clinical guidelines, and improving financial access to care.

Huma Qureshi Pakistan Medical Research Council Islamabad, Pakistan

Dr. Huma Qureshi graduated from Dow Medical College, Karachi in 1979 and did MD in Medicine in 1999 from Karachi University. She has 140 research publications to her credit. In recognition of her outstanding services in Medical Research, she was decorated by the Government of Pakistan with a civil award Tamgha-e-Imtiaz. The Royal College of Physicians, Ireland awarded honorary Fellowship (FRCP) in 2007. She worked as Executive Director (BPS-20), Pakistan Health Research Council, Ministry of National Health Services, Regulation and Coordination, Islamabad from 8th Oct. 2004 to 5th Sept. 2017. In 2007 she conducted the land mark survey on the “Prevalence of Hepatitis B and C in General Population of Pakistan”. The survey has put Pakistan as the 2nd highest HCV prevalence country in the world. She was the focal point for viral hepatitis for the government of Pakistan till 2017.She is a member of the WHO’s viral hepatitis E, B and C testing and treatment guidelines. She has developed the National Hepatitis Strategic Framework 2017-21 for Pakistan. As a WHO consultant, she helped Afghanistan in developing its HCV testing and treatment guidelines and refining its national hepatitis strategic framework. She is the Vice Chair for Pandemic Influenza Preparedness (PIP) framework of WHO.

Indri Oktaria Sukmaputri Ministry of Health, Republic of Indonesia Jakarta, Indonesia

Dr. Sukmaputri is currently the Head of Hepatitis Section at the Ministry of Health, Indonesia. She earned an MD from Universitas Padjadjaran in Indonesia and worked as an Emergency Department and ICU physician, before transitioning to a public health career at the Ministry of Health. She attended UCLA where she received a master’s Degree in Public Health with a specialization in epidemiology. In her role as National HIV treatment policy and guidelines focal point, she has pioneered a project scaling up the ARV treatment (SUFA), resulting in a vast expansion of ART services and a significant increase in the number of PLHIV accessing ARV treatment in Indonesia. She has co-authored over 10 publications. Currently as Head of Hepatitis Section at the Ministry of Health, she is charged with developing policies, guidelines, and interventions, and oversees the management and analysis of data relating to Hepatitis. She is experienced in developing the comprehensive interventions and establishes networks between healthcare facilities for providing Hepatitis, HIV and STI services with the vast area & geographical challenges in Indonesia. She has involved in several operational researche such as part of steering committee to provide guidance on the study.

Jinlin Hou Southern Medical University China Guangzhou, China

Professor JinlinHou is the Director and Professor of the Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University. Professor Hou is the president of APASL 2017 and the president of Chinese Medical Association of Infectious Diseases. Professor Hou joined the University Department of Medicine of Nanfang Hospital in July 1984. Between 1993 and 1994, he received training in the Department of Medicine at St. Mary’s Hospital Medical School in London, UK. Between 2000 and 2001, Professor Hou was a visiting Fellow at the Institute of Hepatology, London, UK. He has been invited to deliver talks at both national and international liver conferences owing to his expertise in viral hepatitis and other liver diseases. His current research interests include the clinical management of liver and Infectious Diseases and the molecular virology and immunology of hepatitis virus infection. He has published more than 300 articles in both national and international journals, including GUT, Hepatology, Journal of Immunology, Journal of Hepatology, Science et al.

Nii Akwei Addo College of Physicians and Surgeons , Ghana

A Public Health Physician Specialist, Senior Genitourinary Medicine and Venereologist with over 25 years of experience especially in the African region. His commitment to public health is evident in his professional experience and MPH training. He has worked in various clinical and managerial positions in the Ghanaian national health system from the district through the regional up to the national levels. As a health systems manager, he supervised technical staff in health at all these levels. He has extensive experience working with technical experts and advisors both in country and from outside the country, and from the public and private sectors. In addition, he has extensive experience in other African countries as a consultant for WHO, and WAHO. During the past 20 years he concentrated on HIV/AIDS, especially development and establishment of the National Comprehensive Prevention, Treatment, Care and Support Program as the Program Manager of the National AIDS/STI Control Program of Ghana. He was a member of the national steering committee for the development of the first and second Ghana National HIV/AIDS/STI Policy documents. He was a member of the national steering committee and co-lead of the prevention, treatment, care and support technical working group for the development of the Ghana National HIV/AIDS Strategic Plan 2006 to 2010 and 2011 to 2015. He has been a Part-time lecturer in Disease Control at the School of Public Health, , External Examiner in Clinical Microbiology, KNUST, Part-time lecturer in Public Health at the Public Health Faculty of the Ghana College of Physician and Surgeons, Reviewer of PHD applications NMIMR. He has vast experience in development and review of WHO Guidelines having undertaken consultancies for the African Regional Office of WHO.

Nije Ramatouilie International Agency for Research in Cancer Fajara,

Dr Ramou Njie is Gambian-born, UK-trained Gastroenterologist & Hepatologist with interests in the link between viral infections, particularly viral hepatitis, and cancer. She set up and conducted a viral hepatitis treatment and liver disease clinic as a UK NHS consultant from 2008- 2011, prior to taking up the post of Hepatologist and head of the Gambia Hepatitis Intervention Study (GHIS) with IARC in June 2011. Her focus over the past 8 years has been two-fold: first, follow-up and intensive surveillance for the presence of liver disease/cancer of the initial GHIS cohort of HBV vaccinated/unvaccinated infants recruited at birth between 1986-1990; second, the setting up of the first viral hepatitis ( predominantly HBV) screening, treatment & monitoring program in SSA as the Principal Investigator of the EU-funded, multi-center PROLIFICA project in Gambia from 2011-2016. The latter resulted in the establishment and follow-up of 2 Gambian cohorts of chronic HBsAg-infected individuals, one of which consists of patients who have been on treatment with oral Tenofovir from 2012 to date. Dr Njie is a member of several national, regional and international professional bodies and is a Fellow of the UK Royal College as well as the West African College of Physicians.

Olivier Segeral Agence Nationale de Recherche sur le Sida et les hépatites virales Phnom Penh, Cambodia

Olivier SEGERAL is a medical doctor, with a professional experience in infectious diseases and public health, specifically for the treatment and care of people living with HIV and viral hepatitis B and C. Previously hospital practitioner in the internal medicine department of the University Hospital Paris Sud, he works since October 2015 in the University of Health Science in Phnom Penh as an assistant coordinator for ANRS research programs on HIV/AIDS and viral hepatitis. Holder of a Master of Public health in resource-limited setting, he was one of the coordinators of the ESTHER initiative in Cambodia. He is involved in several clinical research studies conducted by ANRS and coordinating investigator of the ANRS 12345 TA PROHM study “Tenofovir as prevention of hepatitis B mother-to-child transmission”. He is a member of the Coordinate Action 45 “Clinical Research Viral Hepatitis North and South” of ANRS.

Rakesh Aggarwal Jawaharlal Institute of Postgraduate Medical Education and Research Puducherry, India

Dr. Aggarwal is a Director at Jawaharlal Institute of Postgraduate Medical Education and Research, India. Besides gastroenterology and hepatology, he has received formal training in epidemiology and laboratory work. The primary area of his research work has been viral hepatitis. He has undertaken several studies on epidemiologic, clinical, molecular and immunologic aspects of various forms of viral hepatitis. Other areas of his interest include immunization and health economics. He is a member of several national and international groups, including WHO’s Scientific and Technical Advisory Group on Viral Hepatitis and WHO’s Strategic Advisory Group of Experts on Immunization. He is also the President-Elect of the Indian Association for the Study of Liver. He is actively engaged in treating patients with hepatitis C and has recently published papers based on his experiences in this field (Goel A, et al. Indian J Gastroenterol. 2017 Jun 28. doi: 10.1007/s12664-017-0763-3; Goel A, et al. Indian J Gastroenterol. 2017; 36:137-140). In addition, he was the lead author on a mathematical modelling study to assess the cost-effectiveness analysis of treatment of hepatitis C using generic direct-acting anti-viral drugs in India (Aggarwal R, et al. PLoS One. 2017; 12:e0176503).

Sarah Schillie U.S. Centers of Disease Control and Prevention Atlanta, United States

Dr. Schillie has been a medical epidemiologist with the CDC’s Division of Viral Hepatitis since 2011. In this capacity, she has developed national guidance for use of Hepatitis B vaccine among infants, children, and adults, including health-care personnel and adults with diabetes. She is a graduate of the University of Missouri School of Medicine and completed her pediatrics residency training at Pennsylvania State University and her preventive medicine residency training at SUNY-Stony Brook. She received her MPH from Columbia University and her MBA from Long Island University. Prior to her current role, Dr. Schillie served as a CDC Epidemic Intelligence Service Officer (2007-2009), a CDC chronic disease field epidemiology assignee (2009-2011), and the Suffolk County Department of Health Director of Performance Improvement (2003-2007).

Su Wang Center for Asian Health Colombia, United States

Su Wang, MD, MPH is the Medical Director of the Center for Asian Health, a comprehensive medical practice serving the Asian community in New Jersey. Dr. Wang practices internal medicine and leads the Center’s growth, outreach and grant programs as part of Saint Barnabas Medical Center (SBMC) and the RWJBH network. Previously, she directed the Hepatitis B Program at Charles B. Wang Community Health Center in New York City, where she led its nationally recognized programs in primary care-based hepatitis B care and community based participatory research. Dr. Wang is on the Executive Board for the World Hepatitis Alliance, an international partner with the World Health Organization (WHO) representing viral hepatitis patients and global efforts to eliminate viral hepatitis by 2030, a goal adopted by WHO. She has served as primary investigator for hepatitis B screening and linkage-to-care grants sponsored by the CDC and other funders, and is the lead for the FOCUS Hepatitis B/C screening program at the SBMC Emergency Department. She is the Co-Chair of the New Jersey Hepatitis B Coalition and involved with Hepatitis B United, a national coalition representing community efforts in the U.S. She is an associate member of the Rutgers’ Institute for Health, Health Care Policy and Aging Research and a member of the Physician Strategic Council for the RWJBH Combined Medical Group. She received her medical degree from the University of Miami as part of the Honors Program in Medicine and obtained her Masters of Public Health from Johns Hopkins School of Public Health. Dr. Wang completed a combined Internal Medicine and Pediatric residency at Georgetown University Hospital and then served as an Epidemic Intelligence Service officer for the Centers for Disease Control and Prevention (CDC) at the Food and Drug Administration.